GlassScriptPhysician profile
Nafiseh Hashemi
NPI 1619264645
$12,013.38
in general payments reported to CMS, 2019-2025
30 companies · $2,618 in 2025
The $2,618 reported for 2025 was more than what 84% of Neuro-Ophthalmology providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $640 · 2021: $1,104 · 2022: $1,255 · 2023: $1,540 · 2024: $2,862 · 2025: $2,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,408 · Education: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,407.62 |
| Education | $611.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,297.55 | 2024-2025 | Uplizna, Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $1,634.63 | 2019 | |
| Horizon Therapeutics Plc | $1,271.60 | 2019-2023 | Uplizna, Tepezza |
| Alcon Vision LLC | $1,028.10 | 2022-2025 | Eysuvis, Rocklatan, Clareon |
| Alexion Pharmaceuticals, INC. | $977.67 | 2020-2025 | Ultomiris, Soliris |
| Bausch & Lomb Americas INC. | $836.01 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Merz Pharmaceuticals, LLC | $615.32 | 2021-2025 | Xeomin |
| Sun Pharmaceutical Industries INC. | $497.97 | 2021-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $267.40 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $255.72 | 2020-2023 | |
| Allergan, INC. | $246.56 | 2020-2022 | |
| Dompe US, INC. | $237.52 | 2021-2025 | Oxervate |
| Merz North America, INC. | $231.57 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $223.37 | 2024-2025 | Xdemvy |
| Catalyst Pharmaceuticals, INC. | $195.18 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $173.74 | 2022-2025 | Tyrvaya, Ryzumvi |
| Akorn Operating Company LLC | $150.04 | 2021 | |
| Kala Pharmaceuticals, INC. | $142.51 | 2021-2022 | |
| Biogen, INC. | $134.89 | 2020 | |
| Emd Serono, INC. | $118.57 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $100.00 | 2019 | |
| Abbvie INC. | $73.52 | 2022 | |
| Pfizer INC. | $54.98 | 2024-2025 | |
| Ucb, INC. | $52.01 | 2025 | Zilbrysq |
| Shire North American Group INC | $46.12 | 2019 | |
| Akorn, INC. | $43.55 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Springworks Therapeutics, INC. | $27.25 | 2025 | Gomekli |
| Thea Pharma INC. | $22.27 | 2023 | Iyuzeh |
| Travere Therapeutics, INC. | $18.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nafiseh Hashemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.